All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors
- PMID: 20560996
- PMCID: PMC6493870
- DOI: 10.1111/j.1755-5949.2010.00162.x
All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors
Abstract
Background: The dopamine D2 receptor is the common target for antipsychotics, and the antipsychotic clinical doses correlate with their affinities for this receptor. Antipsychotics quickly enter the brain to occupy 60-80% of brain D2 receptors in patients (the agonist aripiprazole occupies up to 90%), with most clinical improvement occurring within a few days. The D2 receptor can exist in a state of high-affinity (D2(High) ) or in a state of low-affinity for dopamine (D2Low).
Aim: The present aim is to review why individuals with schizophrenia are generally supersensitive to dopamine-like drugs such as amphetamine or methyphenidate, and whether the D2(High) state is a common basis for dopamine supersensitivity in the animal models of schizophrenia.
Results: All animal models of schizophrenia reveal elevations in D2(High) receptors. These models include brain lesions, sensitization by drugs (amphetamine, phencyclidine, cocaine, corticosterone), birth injury, social isolation, and gene deletions in pathways for NMDA, dopamine, GABA, acetylcholine, and norepinephrine.
Conclusions: These multiple abnormal pathways converge to a final common pathway of dopamine supersensitivity and elevated D2(High) receptors, presumably responsible for psychotic symptoms. Although antipsychotics alleviate psychosis and reverse the elevation of D2(High) receptors, long-term antipsychotics can further enhance dopamine supersensitivity in patients. Therefore, switching from a traditional antipsychotic to an agonist antipsychotic (aripiprazole) can result in psychotic signs and symptoms. Clozapine and quetiapine do not elicit parkinsonism or tardive dyskinesia because they are released from D2 within 12 to 24 h. Traditional antipsychotics remain attached to D2 receptors for days, preventing relapse, but allowing accumulation that can lead to tardive dyskinesia. Future goals include imaging D2(High) receptors and desensitizing them in early-stage psychosis.
Conflict of interest statement
The author is also affiliated with Clera, Inc., a pharmaceutical company, but has no other competing interests.
Figures







Similar articles
-
Dopamine D2 receptors as treatment targets in schizophrenia.Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. Clin Schizophr Relat Psychoses. 2010. PMID: 20643630 Review.
-
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.Psychother Psychosom. 2017;86(4):189-219. doi: 10.1159/000477313. Epub 2017 Jun 24. Psychother Psychosom. 2017. PMID: 28647739 Review.
-
Psychosis pathways converge via D2high dopamine receptors.Synapse. 2006 Sep 15;60(4):319-46. doi: 10.1002/syn.20303. Synapse. 2006. PMID: 16786561 Review.
-
Schizophrenia and dopamine receptors.Eur Neuropsychopharmacol. 2013 Sep;23(9):999-1009. doi: 10.1016/j.euroneuro.2013.06.005. Epub 2013 Jul 13. Eur Neuropsychopharmacol. 2013. PMID: 23860356 Review.
-
Atypical antipsychotics: mechanism of action.Can J Psychiatry. 2002 Feb;47(1):27-38. Can J Psychiatry. 2002. PMID: 11873706 Review.
Cited by
-
Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms.J Psychopharmacol. 2016 Aug;30(8):749-70. doi: 10.1177/0269881116654697. Epub 2016 Jul 1. J Psychopharmacol. 2016. PMID: 27371498 Free PMC article. Review.
-
Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia.Ther Adv Psychopharmacol. 2022 Jan 28;12:20451253211064396. doi: 10.1177/20451253211064396. eCollection 2022. Ther Adv Psychopharmacol. 2022. PMID: 35111295 Free PMC article.
-
Dopamine receptor homooligomers and heterooligomers in schizophrenia.CNS Neurosci Ther. 2011 Feb;17(1):52-7. doi: 10.1111/j.1755-5949.2010.00228.x. Epub 2010 Dec 28. CNS Neurosci Ther. 2011. PMID: 21199449 Free PMC article. Review.
-
Schizophrenia diagnosis and treatment.CNS Neurosci Ther. 2011 Apr;17(2):81-2. doi: 10.1111/j.1755-5949.2011.00250.x. CNS Neurosci Ther. 2011. PMID: 21401910 Free PMC article. No abstract available.
-
Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia.Biol Psychiatry. 2018 Apr 15;83(8):707-714. doi: 10.1016/j.biopsych.2017.11.032. Epub 2017 Dec 7. Biol Psychiatry. 2018. PMID: 29325847 Free PMC article.
References
-
- Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987;91:415–433. - PubMed
-
- Curran C, Byrappa N, McBride A. Stimulant psychosis: Systematic review. Brit J Psychiat 2004;185:196–204. - PubMed
-
- Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 2000;20:423–451. - PubMed
-
- Zemlan FP, Hirschowitz J, Garver DL. Relation of clinical symptoms to apomorphine‐stimulated growth hormone release in mood‐incongruent psychotic patients. Arch Gen Psychiat 1986;43:1162–1167. - PubMed
-
- Seeman P, Nam D, Ulpian C, Liu IS, Tallerico T. New dopamine receptor, D2Longer, with unique TG splice site, in human brain. Brain Res Mol Brain Res 2000;76:132–141. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical